Talk:Ancillary testing in prostate cancer

From Libre Pathology

Revision as of 15:17, 1 November 2022 by Michael (talk | contribs) (Created page with "MSI testing - in BRCA1/2: {{cite journal |vauthors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

MSI testing - in BRCA1/2: "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA". J Immunother Cancer 8 (2). August 2020. doi:10.1136/jitc-2020-001065. PMC 7422632. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/.

Retrieved from "https://librepathology.org/w/index.php?title=Talk:Ancillary_testing_in_prostate_cancer&oldid=52199"